Future Directions and Unmet Needs in Relapsed/Refractory MCL
A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.
Read More
Sequencing Therapies in the Third-Line and Beyond Setting for MCL
A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.
Read More
ASH 2023 Updates on Frontline Therapies in MCL
A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.
Read More
Unmet Needs in Treating Relapsed/Refractory FL
Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.
Read More
Sequencing Immunotherapy in the Third-line and Beyond Setting for FL
Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.
Read More
Choosing CAR T-cells as Third-line and Beyond Therapy for FL
Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.
Read More
Choosing Bispecific T-cell Engager as Third-line and Beyond Therapy for FL
A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.
Read More
Zanubrutinib as Third-Line and Beyond Therapy for FL
Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.
Read More
Tazemetostat as Third-line and Beyond Therapy for FL
Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.
Read More
Bispecific T-cell Engagers as Third-line and Beyond Therapy for FL
Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.
Read More
CAR T-cells as Third-line and Beyond Therapy for FL
Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.
Read More
ASH 2023 Updates on Frontline Therapies in FL
A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.
Read More